TAVI

Last articles on TAVR

The latest scientific articles on TAVI published on our website

01- TAVR and Anticoagulation: Direct Anticoagulant Agents or Vitamin K Inhibitors? In some patients, using an&nbsp;anticoagulant agent&nbsp;is not an option, it is just prescribed. Based on the French&nbsp;TAVR&nbsp;registry, this research compared&nbsp;long-term mortality,&nbsp;bleeding,&nbsp;and ischemic events&nbsp;after&nbsp;valve implantation.&nbsp;A comparison was made between&nbsp;TAVR and direct vs. classic anticoagulant agents—good old proven and reversible vitamin&nbsp;K inhibitors. Read also HERE 02-<a href="https://solaci.org/en/2021/10/05/the-latest-scientific-articles-on-tavi-published-on-our-website/" title="Read more" >...</a>

SOLACI-CACI 2021 Virtual

SOLACI-CACI 2021 | Overcoming Challenges of the BALLOON EXPANDABLE TAVI Cases &#8211; EDWARDS Symposium

&#x2714;&#xfe0f; Watch again the Edwards Lifesciences Symposium in the SOLACI-CACI 2021 Virtual Congress.&#x2714;&#xfe0f; Topic: Overcoming Challenges of the BALLOON EXPANDABLE TAVI Cases.  &#x1f468;&#x200d;&#x1f3eb; Program: 00:05 &#8211; Opening &#8211; Dr. José Mangione (BRA). 02:20 &#8211; Aortic VinV in small annuli: Does the final gradient matter? &#8211; Dr. Adolfo Ferrero (ARG). 21:14 &#8211; Small Annuli and<a href="https://solaci.org/en/2021/09/13/solaci-caci-2021-overcoming-challenges-of-the-balloon-expandable-tavi-cases-edwards-symposium-2/" title="Read more" >...</a>

ESC 2021 | ENVISAGE-TAVI AF: sorpresas con el endoxaban en TAVI y fibrilación auricular

ESC 2021 | ENVISAGE-TAVI AF: Surprise with Endoxaban in TAVR and Atrial Fibrillation

The enthusiasm for direct oral anticoagulants after transcatheter aortic valve replacements (TAVR) is waning. At least, when it combines with atrial fibrillation. The ENVISAGE-TAVI AF has shown excessive bleeding with endoxaban vs. the classical vitamin K antagonists. Endoxaban resulted non-inferior to vitamin K antagonists in terms of net clinical adverse events, but major bleeding events<a href="https://solaci.org/en/2021/09/10/esc-2021-envisage-tavi-af-surprise-with-endoxaban-in-tavr-and-atrial-fibrillation/" title="Read more" >...</a>

Sangrados mayores en pacientes con AAS más rivaroxabán

AAS vs DAPT post TAVI: Meta-Analysis of Randomized Studies

Aspirin monotherapy (ASA) reduced the combined risk of thrombotic and bleeding events compared against dual antiplatelet therapy (DAPT) in patients receiving transcatheter aortic valve replacement (TAVR). This meta-analysis has only reproduced smaller randomize study outcomes and does not include the OCEAN-TAVI registry, the only one that has shown something different so far.&nbsp; Even though ASA<a href="https://solaci.org/en/2021/06/14/aas-vs-dapt-post-tavi-meta-analysis-of-randomized-studies/" title="Read more" >...</a>

Top